The enteral form of carbidopa and levodopa can be administered in various ways, depending on the patient’s needs and the formulation provided by the healthcare provider.
Oral Tablets (for patients who can swallow pills):
- Sinemet and other brand names provide carbidopa and levodopa in tablet form. These should be taken with a glass of water, typically 30 minutes before or 1 hour after meals. It is important to avoid high-protein meals when taking carbidopa/levodopa as they may reduce the absorption of levodopa.
Enteral Feeding Tube (for patients with swallowing difficulties):
For patients who use a feeding tube, carbidopa and levodopa enteral therapy can be administered as a liquid or suspended form, depending on the specific medication prescribed. This form is typically delivered via a gastrostomy tube (G-tube), nasogastric tube (NG-tube), or another form of enteral feeding system.
Steps for Tube Administration:
- Prepare the Medication: If using the tablet form, crush the prescribed dose of the medication. Consult with a healthcare provider or pharmacist to ensure the medication can be safely crushed.
- Mix with Liquid: After crushing the tablet, mix the medication with a small amount of water or other approved liquid.
- Administer: Pour the medication mixture into the feeding tube, ensuring it is delivered correctly.
- Flush the Tube: After administering the medication, flush the tube with water to ensure that the medication is properly delivered and to prevent clogging of the tube.
The healthcare provider will give specific guidance on the dosage, frequency, and monitoring required when using enteral forms of carbidopa and levodopa.
Levodopa:
Levodopa, or L-DOPA, is a precursor to dopamine, which is the neurotransmitter deficient in the brains of people with Parkinson’s disease. Since dopamine cannot cross the blood-brain barrier, levodopa is administered to the patient as it can cross this barrier. Once inside the brain, levodopa is converted into dopamine, which helps alleviate motor symptoms of Parkinson’s disease, such as tremors, stiffness, and slowness of movement.
However, when taken orally, levodopa is also converted into dopamine in peripheral tissues (outside the brain), which can result in side effects like nausea, vomiting, and low blood pressure.
Carbidopa:
Carbidopa is added to the combination therapy to address this issue. Carbidopa works by inhibiting the peripheral conversion of levodopa into dopamine. It does this by blocking the enzyme aromatic L-amino acid decarboxylase (AADC), which is responsible for converting levodopa into dopamine in peripheral tissues. By inhibiting this enzyme, carbidopa ensures that more levodopa is available to cross into the brain, where it is converted into dopamine to treat Parkinson’s disease. Carbidopa does not cross the blood-brain barrier, so it does not have a direct effect on Parkinson’s symptoms, but it enables levodopa to work more effectively with fewer side effects.
Enteral Formulation:
The enteral form of carbidopa and levodopa is particularly important for patients who cannot swallow oral tablets, such as those who have swallowing difficulties due to age, illness, or neurological impairments. The enteral form can be administered through feeding tubes such as a gastrostomy tube (G-tube), ensuring continuous or controlled medication delivery to the patient. The enteral form may be available in liquid form or as a suspension that can be infused directly into the stomach.
While carbidopa and levodopa are effective in managing Parkinson’s disease symptoms, they can cause side effects:
Common Side Effects:
- Nausea and Vomiting: Despite the addition of carbidopa, some patients may still experience gastrointestinal issues like nausea.
- Dizziness: This can occur due to low blood pressure (orthostatic hypotension), especially when standing up quickly.
- Dyskinesia: Long-term use of levodopa can lead to involuntary movements (dyskinesia), which may become more prominent over time.
- Fatigue: Some patients experience general fatigue or tiredness while taking the medication.
Serious Side Effects:
- Confusion and Hallucinations: Particularly in older adults or advanced Parkinson’s patients, carbidopa and levodopa may cause confusion, delusions, or hallucinations.
- Cardiovascular Issues: Irregular heartbeats or arrhythmias can occur, especially in patients with pre-existing heart conditions.
- Severe Allergic Reactions: In rare cases, the medication may cause severe allergic reactions, including difficulty breathing, swelling of the face, or a rash.
If any of these side effects occur, it is important to notify a healthcare provider for further evaluation.
Pregnancy and Breastfeeding:
Carbidopa and levodopa should only be used during pregnancy if absolutely necessary. It is not known whether the medication passes into breast milk, so breastfeeding while on this medication should only be considered after consulting with a doctor.
Mental Health Issues:
Patients with a history of psychiatric disorders may experience worsened symptoms, such as delusions or hallucinations. It is important to monitor for these signs, especially in elderly patients.
Cardiovascular Disease:
Patients with cardiovascular disease should use caution, as carbidopa/levodopa can cause arrhythmias and may worsen existing heart conditions.
Kidney and Liver Disease:
Patients with kidney or liver impairment should be monitored closely, as the metabolism and excretion of carbidopa and levodopa may be affected in these patients.
Glaucoma:
Care should be taken in patients with narrow-angle glaucoma, as carbidopa/levodopa may increase the pressure inside the eye.
Carbidopa and levodopa can interact with several other medications, which may require adjustments in dosing:
- Iron Supplements: Iron can interfere with the absorption of levodopa. It is recommended that patients separate the administration of iron supplements and carbidopa/levodopa by at least 2 hours.
- Antipsychotic Drugs: Medications that block dopamine receptors, such as haloperidol or chlorpromazine, can diminish the effectiveness of levodopa. This is especially concerning in patients with Parkinson’s disease who may also experience psychotic symptoms.
- MAO Inhibitors: Monoamine oxidase inhibitors (MAOIs), such as phenelzine, can interact with levodopa and lead to hypertensive crises. This combination should be avoided unless carefully monitored.
- Antihypertensive Medications: Carbidopa and levodopa can lower blood pressure, so care should be taken when combined with antihypertensive drugs, as this may result in significant hypotension.
The dosage of carbidopa and levodopa depends on the severity of the condition and individual patient needs. Typically, treatment begins with a lower dose, which is gradually increased based on therapeutic response. For enteral therapy, it is crucial that healthcare providers tailor the dosage to each patient’s specific condition and monitor for side effects.
Carbidopa and levodopa enteral therapy is available only by prescription. The medication should be prescribed by a healthcare provider with experience in managing Parkinson’s disease, who will determine the appropriate dosage and method of administration based on the patient’s health, age, and response to treatment. Regular follow-up appointments are essential to assess the patient’s progress and adjust treatment as needed